Months af­ter mas­sive Ipsen deal, BAKX Ther­a­peu­tics nets more cash for its 'Thel­ma and Louise' ap­proach to can­cer cell death

BAKX Ther­a­peu­tics emerged from stealth in a big way back in Ju­ly, strik­ing an $852 mil­lion deal with Ipsen for its lead can­cer can­di­date, a small mol­e­cule de­signed to ac­ti­vate the body’s nat­ur­al process for pro­grammed cell death. And Ipsen’s putting a bit more cash in the com­pa­ny’s cof­fers to see that pro­gram in­to the clin­ic.

CEO Sree Kant un­veiled a $25 mil­lion Se­ries A round on Thurs­day, led by AB Mag­ni­tude Ven­tures Group with a hand from Ipsen and Sher­pa Health­care Part­ners. The funds will be used to ad­vance the com­pa­ny’s BAKX ac­ti­va­tor pro­gram, which traces back to pi­o­neer­ing work around apop­to­sis by the Dana-Far­ber Can­cer In­sti­tute’s Loren Walen­sky and Al­bert Ein­stein Col­lege of Med­i­cine’s Evri­pidis Ga­vathi­o­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER